Yescarta in Nepal
How patients in Nepal access Yescarta (axicabtagene ciloleucel) via Named Patient Program.
Yescarta - overview
Yescarta (axicabtagene ciloleucel) is manufactured by Gilead/Kite and indicated for DLBCL, FL. It is a CAR-T (CD19) approved by the US FDA in 2017 and may be accessible to patients in Nepal through a Named Patient Program or personal-import pathway.
Access in Nepal
Nepal's DDA has a personal-use pathway; volumes are small but process exists.
How Reserve Meds coordinates access in Nepal
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Nepal-specific eligibility.
- Treating physician in Nepal issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Yescarta from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Nepal.
Typical timeline for Nepal
End-to-end, most requests are completed in 2-6 weeks. Nepal's tier 3 regulatory maturity typically supports longer processing times.
What patients and physicians in Nepal ask
- Is the pathway legal in Nepal? Yes - it operates under Nepal's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Nepal able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.
Start a request for Yescarta in Nepal
YELLOW
AI Regulatory Review Agent — preliminary signal
Cell/gene therapy to Nepal is technically permissible via personal import but requires specialty cold-chain, autologous collection coordination, and case-by-case regulatory confirmation. Expect 6-12 week lead time.
Rule: gene_therapy_specialty_logistics • Reviewed 2026-04-22